This study has reviewed the post market clinical trials of Proprietary Chinese Medicine, especially those which have published high quality SCI papers to assess the current situation and challenges faced in this area. At the same time, we also listed the registration differences between Food and Drug Administration （FDA）, European Medicine Agency and Health Canada. This study further analyzed the necessity and trend of post marketing evaluation of Proprietary Chinese Medicines.